Evolve Biosystems

What Evolve Biosystems does

Evolve Biosystems, now operating as Infinant Health, is a privately held microbiome science company headquartered in Sacramento, California. Founded around 2011-2015, the company has developed proprietary Bifidobacterium infantis strains (notably EVC001 and H5-positive variants) that demonstrate superior utilization of human milk oligosaccharides (HMOs), enabling colonization of the infant gut when co-administered with breast milk. Its flagship consumer product, Evivo with MCT Oil, is a probiotic marketed direct-to-consumers through the company's e-commerce platform to parents and caregivers of infants, with a secondary channel targeting healthcare professionals (pediatricians, neonatologists) who recommend the product.

The company has raised approximately $125M across five funding rounds between 2014 and 2021, with investors including the Bill & Melinda Gates Foundation, Cargill, Manna Tree, Acre Venture Partners, Horizons Ventures, Bow Capital, Spruce Capital Partners, and Tate & Lyle Ventures. In 2022, the company rebranded from Evolve Biosystems to Infinant Health to reflect a broadened scope beyond consumer probiotics. Building on its core strain technology, the company is developing INF108, a next-generation drug candidate targeting necrotizing enterocolitis (NEC) in premature infants, representing a strategic pivot from over-the-counter probiotics toward regulated pharmaceutical therapeutics. The company maintains a focused single-SKU commercial offering (Evivo with MCT Oil) with geographic operations limited to North America, and operates with a small team of 11-50 employees.

Name

Evolve Biosystems

Legal name

Infinant Health Inc

Website

https://evolvebiosystems.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Evolve Biosystems (now Infinant Health) is a privately held microbiome company that develops proprietary B. infantis probiotic strains, selling its Evivo infant gut health product direct-to-consumers while advancing INF108, a drug candidate to prevent NEC in premature infants.

Ownership category

akta.pro rank

Product category

Infant Microbiome Probiotics

NAICS

Food Manufacturing (311), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Food And Kindred Products (2000), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Baby Feeding Supplements & Fortifiers (Probiotics, DHA/ARA, Vitamins) (CRADAEAI)

akta.pro secondary industries

Probiotics & Digestive Health Supplements (CRADAGAF), Premature & Low-Birth-Weight Infant Formula Manufacturing (AFAHAHAE), Infant Formula & Specialized Dairy Nutrition Manufacturing (AFAKAKAJ)

Keywords

• Infant microbiome probiotics
• Gut microbiome therapeutics
• B. infantis supplements
• NEC drug development
• Pediatric probiotic products

Headquarters

HQ city

Davis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Evivo Product Sales: Direct-to-consumer sales of Evivo probiotic products, including Evivo with MCT Oil, targeting parents and caregivers of infants to support gut microbiome health.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Infinant Health (formerly Evolve Biosystems) manufactures and sells Evivo with MCT Oil, an infant probiotic built on its proprietary B. infantis EVC001 strain that, when used alongside breast milk, establishes a healthy infant gut microbiome. The company is also developing INF108, a next-generation drug strain derived from B. infantis EVC001 designed to prevent necrotizing enterocolitis (NEC) in premature infants. Sales are conducted primarily direct-to-consumer via the company's own e-commerce platform, with a parallel healthcare-professional recommendation channel.

Product overview

Evolve Biosystems, now operating as Infinant Health, offers a focused portfolio of microbiome-based products centered on the B. infantis EVC001 strain. The core consumer product is Evivo with MCT Oil, a probiotic for infants used alongside breast milk. Building on this strain technology, the company is developing INF108 as a next-generation therapeutic candidate targeting NEC in premature infants. The product line is unified around B. infantis H5-positive strains that show enhanced fitness advantages in HMO utilization.

Differentiator

Problem solved

Functional benefit

Products and services

• Evivo with MCT Oil An infant probiotic product built on the proprietary B. infantis EVC001 strain that, when used in combination with breast milk, helps establish a healthy infant gut microbiome. Sold direct-to-consumer to parents and caregivers of infants through the Infinant Health e-commerce site, with a parallel recommendation channel targeting pediatricians and neonatologists.
• INF108 A next-generation drug strain based on the proprietary B. infantis EVC001 lineage, designed to prevent necrotizing enterocolitis (NEC) in premature infants when used in combination with breast milk. Positioned as a clinical-stage therapeutic candidate within the company's microbiome pipeline.
• B. infantis EVC001 (proprietary strain platform) Pioneering proprietary B. infantis strain that forms the scientific foundation of the company's products; H5-positive strain variants demonstrate superior HMO utilization with enhanced growth on lacto-N-tetraose and lacto-N-neotetraose and significant fitness advantages over H5-negative strains.

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Bobbie: Bobbie is a DTC-first U.S. infant formula brand built around scientifically differentiated ingredients and direct relationships with parents. Comparable to Infinant Health in the DTC premium infant nutrition niche targeting health-conscious parents.
• ByHeart: ByHeart is a U.S. infant formula company selling direct-to-consumer with an emphasis on clinical-grade ingredients and proprietary nutrition formulations. Directly comparable to Infinant Health's DTC premium infant nutrition positioning.
• BioGaia: BioGaia is a Swedish probiotics company with a long-established infant probiotic portfolio (e.g., L. reuteri strains) sold through pharmacies and pediatricians globally. Closest direct competitor to Infinant Health in the infant probiotic category.
• Culturelle (i-Health / Chr. Hansen): Culturelle markets pediatric probiotic supplements (including for infants/children) through mass retail and pharmacy channels. Comparable as a branded infant probiotic competing for the same parental purchaser.

Emerging players

• Biomilq: Biomilq is developing cell-cultured human milk components as an alternative to infant formula. Comparable as an emerging science-driven infant nutrition company targeting the same health-conscious parent segment with novel microbiome/milk biology.

Broad incumbents

• Nestlé (NAN / Gerber): Nestlé operates the largest global infant nutrition portfolio (NAN, Gerber) and is investing in microbiome science. Comparable as the dominant incumbent with the distribution and R&D scale Infinant Health would need to partner with or compete against.
• Danone (Nutricia): Danone's Nutricia division is a global leader in infant formula and medical nutrition, with growing microbiome research. Comparable as a broad incumbent in infant specialty nutrition and a likely potential acquirer or distributor.
• Reckitt (Mead Johnson / Enfamil): Reckitt owns Mead Johnson (Enfamil), a global infant formula leader with established pediatrician relationships. Comparable as a broad incumbent competing in premium and specialty infant nutrition.
• Abbott (Similac): Abbott's Similac line is one of the two leading U.S. infant formula brands. Comparable as a broad incumbent with hospital channel presence relevant to Infinant Health's pediatric and NICU-focused commercial strategy.

Others

• Novonesis (Novozymes / Chr. Hansen): Novonesis (formed from Novozymes and Chr. Hansen merger) is a global leader in microbial and probiotic strain production, supplying infant formula and supplement manufacturers. Comparable as the enabling probiotic strain supplier ecosystem that Infinant Health's proprietary strain platform competes within.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/evolvebio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evolve Biosystems